KAT681 is a liver-selective thyromimetic agent used to modulate lipoprotein metabolism; it significantly lowers plasma cholesterol and triglyceride levels by upregulating hepatic LDL receptor and scavenger receptor class B type I (SR-BI) expression without affecting cholesteryl ester transfer protein activity.